JP3822641B2 - 軌道用の防音装置 - Google Patents

軌道用の防音装置 Download PDF

Info

Publication number
JP3822641B2
JP3822641B2 JP54125697A JP54125697A JP3822641B2 JP 3822641 B2 JP3822641 B2 JP 3822641B2 JP 54125697 A JP54125697 A JP 54125697A JP 54125697 A JP54125697 A JP 54125697A JP 3822641 B2 JP3822641 B2 JP 3822641B2
Authority
JP
Japan
Prior art keywords
sound absorbing
absorbing plate
sound
plate
divided
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP54125697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000510921A5 (enExample
JP2000510921A (ja
Inventor
ベルンハルト ノイマン、
Original Assignee
グムンドナー ファーテイクタイレ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コムパニ コマンデイトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT93496A external-priority patent/AT403809B/de
Priority claimed from AT0101596A external-priority patent/AT405426B/de
Application filed by グムンドナー ファーテイクタイレ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コムパニ コマンデイトゲゼルシャフト filed Critical グムンドナー ファーテイクタイレ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コムパニ コマンデイトゲゼルシャフト
Publication of JP2000510921A publication Critical patent/JP2000510921A/ja
Publication of JP2000510921A5 publication Critical patent/JP2000510921A5/ja
Application granted granted Critical
Publication of JP3822641B2 publication Critical patent/JP3822641B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01B—PERMANENT WAY; PERMANENT-WAY TOOLS; MACHINES FOR MAKING RAILWAYS OF ALL KINDS
    • E01B19/00—Protection of permanent way against development of dust or against the effect of wind, sun, frost, or corrosion; Means to reduce development of noise
    • E01B19/003—Means for reducing the development or propagation of noise

Landscapes

  • Engineering & Computer Science (AREA)
  • Architecture (AREA)
  • Civil Engineering (AREA)
  • Structural Engineering (AREA)
  • Building Environments (AREA)
  • Soundproofing, Sound Blocking, And Sound Damping (AREA)
  • Railway Tracks (AREA)
  • Power-Operated Mechanisms For Wings (AREA)
  • Devices Affording Protection Of Roads Or Walls For Sound Insulation (AREA)
  • Signal Processing Not Specific To The Method Of Recording And Reproducing (AREA)
  • Noise Elimination (AREA)
  • Magnetic Heads (AREA)
  • Holo Graphy (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Bridges Or Land Bridges (AREA)
JP54125697A 1996-05-29 1997-05-23 軌道用の防音装置 Expired - Fee Related JP3822641B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AT93496A AT403809B (de) 1996-05-29 1996-05-29 Schallschutzeinrichtung für gleise
AT934/96 1996-06-11
AT1015/96 1996-06-11
AT0101596A AT405426B (de) 1996-06-11 1996-06-11 Schienengleiche eindeckung für gleise
PCT/AT1997/000109 WO1997045592A1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise

Publications (3)

Publication Number Publication Date
JP2000510921A JP2000510921A (ja) 2000-08-22
JP2000510921A5 JP2000510921A5 (enExample) 2005-01-13
JP3822641B2 true JP3822641B2 (ja) 2006-09-20

Family

ID=25594370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54125697A Expired - Fee Related JP3822641B2 (ja) 1996-05-29 1997-05-23 軌道用の防音装置

Country Status (14)

Country Link
US (1) US6253872B1 (enExample)
EP (1) EP0901536B1 (enExample)
JP (1) JP3822641B2 (enExample)
CN (1) CN100424268C (enExample)
AT (1) ATE229595T1 (enExample)
AU (1) AU738889B2 (enExample)
CA (1) CA2255946C (enExample)
DE (1) DE59708955D1 (enExample)
DK (1) DK0901536T3 (enExample)
ES (1) ES2186891T3 (enExample)
HU (1) HU221872B1 (enExample)
NO (1) NO316078B1 (enExample)
TW (1) TW345603B (enExample)
WO (1) WO1997045592A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530413A (ja) * 2013-07-07 2016-09-29 ４・サイレンス・ベスローテン・フエンノートシャップ４Ｓｉｌｅｎｃｅ Ｂ．Ｖ． 音を回折させるための回折器

Families Citing this family (310)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19812481C2 (de) * 1998-03-21 2002-08-22 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
DE29905550U1 (de) * 1999-03-26 2000-08-24 DVG Deutsche Verpackungsmittel GmbH, 90552 Röthenbach Absorptionsbelag zur Reduzierung der Schallabstrahlung für Gleiskörper
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US6481637B1 (en) * 2000-11-20 2002-11-19 Mcqueen Philip Jeffrey Rail pad and method for strain attentuation
DE10111919A1 (de) * 2001-03-13 2002-09-19 Boegl Max Bauunternehmung Gmbh Fahrwegträger
HU224236B1 (hu) * 2001-12-14 2005-06-28 Attila Szebeni Vasúti acélhidaknál alkalmazható, egymáshoz csatlakoztatott elemekbõl álló, zaj- és rezgéscsökkentett mûanyag járólemezrendszer
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
AT6414U1 (de) * 2002-07-17 2003-10-27 Gmundner Fertigteile Gmbh Gleisabdeckung
GB2399123B (en) * 2003-03-05 2006-03-01 Corus Uk Ltd Rail damper
WO2004099162A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Polycyclic diazodioxide-based bcl-2 protein antagonist
US20040242886A1 (en) * 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20100126797A1 (en) * 2004-02-12 2010-05-27 Humphries Eric C Panel Assembly For Traffic Noise Barrier Wall
US8616331B2 (en) 2004-02-12 2013-12-31 Eric C. Humphries Panel assembly for traffic noise barrier wall
US7546900B2 (en) * 2004-02-12 2009-06-16 Evonik Cyro Llc Panel assembly for traffic noise barrier wall
TWI347390B (en) * 2004-03-05 2011-08-21 Gmundner Fertigteile Gmbh Noise-reducing track cover
JP2007538103A (ja) 2004-05-20 2007-12-27 ザ スクリップス リサーチ インスティテュート トランスサイレチン安定化
NZ588432A (en) 2004-09-17 2012-03-30 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
US20070131480A1 (en) * 2004-12-06 2007-06-14 Corbin Maxwell H Jr Sound arresting barrier
US7464791B2 (en) * 2005-01-27 2008-12-16 Pretty Products, Llc Acoustic mats and methods for making the same
US20060230699A1 (en) * 2005-03-22 2006-10-19 Keene James R Sound control flooring systems and methods therefor
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
WO2007106537A2 (en) * 2006-03-13 2007-09-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
EP2007373A4 (en) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
AU2007260579B2 (en) * 2006-06-13 2012-09-06 Newstyle Nominees Pty Ltd Rail track crossing
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
CN101535304A (zh) 2006-09-21 2009-09-16 埃迪威克斯生物科学公司 丝氨酸水解酶抑制剂
BRPI0715579A2 (pt) 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
JP5013590B2 (ja) * 2006-11-14 2012-08-29 エンデバーハウス株式会社 伸縮性に優れた線路用吸音材
US20080146605A1 (en) 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
BRPI0808089A2 (pt) 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
ES2693948T3 (es) 2007-03-15 2018-12-14 Auspex Pharmaceuticals, Inc. Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
MX2010000465A (es) * 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
CN101855228B (zh) * 2007-09-11 2012-10-24 杏林制药株式会社 作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
AU2008324609B2 (en) * 2007-11-07 2015-04-23 Wai Lun Ho Tunable vibration absorbing device
CA2706465A1 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
PL2947072T3 (pl) 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
US8048204B2 (en) 2008-09-23 2011-11-01 Rwdi Air Inc. Wall assembly
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
PL2401267T3 (pl) * 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
KR101748891B1 (ko) * 2009-03-11 2017-06-19 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
JP2012520314A (ja) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン 癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
US8146310B2 (en) * 2009-03-11 2012-04-03 Keene Building Products Co., Inc. Noise control flooring system
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
AU2010229468A1 (en) 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
AR076363A1 (es) 2009-04-22 2011-06-08 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida
SG175748A1 (en) 2009-04-22 2011-12-29 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
PE20120810A1 (es) 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc Compuestos derivados de 5-ciano-2-(feniltio)bencensulfonamida como antagonistas de ccr3
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
ES2655883T5 (es) 2009-07-08 2022-04-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Composiciones farmacéuticas que contienen tiosulfato de sodio
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
BR112012003661A2 (pt) 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
NL2003697C2 (nl) 2009-10-22 2011-04-26 Univ Twente Weg met geluid-diffractoren.
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US8528286B2 (en) * 2009-11-10 2013-09-10 Keene Building Products Co., Inc. Sound control mat
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2515654A4 (en) * 2009-12-23 2013-04-24 Map Pharmaceuticals Inc NEW ERGOLINANALOGA
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EP2542542B1 (en) 2010-03-02 2015-04-22 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
WO2011116161A2 (en) 2010-03-17 2011-09-22 Axikin Pharmaceuticals Inc. Arylsulfonamide ccr3 antagonists
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011153197A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
CA2801003A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
NZ604018A (en) 2010-06-07 2015-02-27 Novomedix Llc Furanyl compounds and the use thereof
MX347927B (es) 2010-07-19 2017-05-19 Summa Health System Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
US20130303533A1 (en) 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
US8912324B2 (en) 2010-09-01 2014-12-16 Ambit Biosciences Corporation Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
EP2611792B1 (en) 2010-09-01 2017-02-01 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
EP2611502A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
AU2011296024B2 (en) 2010-09-01 2015-05-28 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US20120088769A1 (en) 2010-10-11 2012-04-12 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
US20120125711A1 (en) * 2010-11-24 2012-05-24 Stahr Richard E Sound absorbing panel and system
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2691384B1 (en) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2723735A4 (en) 2011-06-23 2015-02-18 Map Pharmaceuticals Inc NOVEL ANALOGUES OF FLUORO-ERGOLINE
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
MY167575A (en) 2011-10-14 2018-09-20 Ambit Biosciences Corp Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
AU2012355982A1 (en) 2011-12-19 2014-07-10 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
TW201341367A (zh) 2012-03-16 2013-10-16 Axikin Pharmaceuticals Inc ３，５－二胺基吡唑激酶抑制劑
SI2844637T1 (en) 2012-05-02 2018-07-31 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof
US9732038B2 (en) 2012-06-14 2017-08-15 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
US9156799B2 (en) 2012-09-07 2015-10-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
US20150272924A1 (en) 2012-11-08 2015-10-01 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
AU2013352106B2 (en) 2012-11-30 2018-04-26 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
CA2895829A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
CN105683182A (zh) 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3450571B1 (en) 2014-02-24 2023-04-05 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
TWI705967B (zh) 2014-03-20 2020-10-01 美商卡佩拉醫療公司 苯并咪唑衍生物及其醫藥組合物及使用方法
CA3175724C (en) 2014-03-20 2024-01-09 Capella Therapeutics, Inc. Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
EP3142649B1 (en) 2014-05-12 2019-07-24 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitor emricasan
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
JP2017526713A (ja) 2014-09-12 2017-09-14 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック併用療法
EP3209658A1 (en) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoid derivatives and methods of use thereof
EP3789039A1 (en) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
CN107428749B (zh) 2015-01-28 2020-07-24 上海复旦张江生物医药股份有限公司 取代的咪唑并[1,2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2016210180A2 (en) 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
IL284874B2 (en) 2015-10-30 2023-10-01 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP4455145A3 (en) 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Piperidinyl nociceptin receptor compounds
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
EP3397251A1 (en) 2015-12-31 2018-11-07 Conatus Pharmaceuticals, Inc. Methods of using caspase inhibitors in treatment of liver disease
MX385964B (es) 2016-01-08 2025-03-18 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
EP3399978B1 (en) 2016-01-08 2020-09-09 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10064855B2 (en) 2016-03-08 2018-09-04 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
WO2017156183A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
EP4190357A1 (en) 2016-05-13 2023-06-07 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
MX389710B (es) 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
DE102016111064A1 (de) * 2016-06-16 2017-12-21 Vossloh-Werke Gmbh Elastisches Element für einen Befestigungspunkt für eine Schiene für Schienenfahrzeuge und Befestigungspunkt
CN106087611B (zh) * 2016-06-20 2019-07-12 勾厚渝 轨道交通构件
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
MX390121B (es) 2016-09-19 2025-03-20 Mei Pharma Inc Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102431830B1 (ko) 2016-11-07 2022-08-16 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018089427A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
TW202345829A (zh) 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
KR20230169457A (ko) 2017-01-27 2023-12-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2018220515B2 (en) 2017-02-17 2022-06-30 DayLife LLC Universal antivenom
CN116730920A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
KR20190133198A (ko) 2017-03-27 2019-12-02 셀진 코포레이션 면역원성의 감소를 위한 방법 및 조성물
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CA3067416A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. Use of anti-fam19a5 antibodies for treating cancers
CN111344011B (zh) 2017-06-27 2024-01-26 纽洛可科学有限公司 抗fam19a5抗体用于治疗纤维化的用途
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体及びその用途
JP6904616B2 (ja) 2017-06-27 2021-07-21 ニューラクル サイエンス カンパニー リミテッド 緑内障治療のための配列相同性を有するファミリー、メンバーａ５抗体の用途
ES2953032T3 (es) 2017-09-01 2023-11-07 Univ East Carolina Métodos ex vivo para la activación de las células inmunológicas
RS66714B1 (sr) 2017-09-21 2025-05-30 Neurocrine Biosciences Inc Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
CN111263820B (zh) 2017-10-02 2024-07-02 纽洛可科学有限公司 抗序列相似家族19成员a5抗体用于治疗和诊断情绪障碍的用途
CA3076920A1 (en) 2017-10-04 2019-04-11 The Regents Of The University Of California Immunomodulatory oligosaccharides
MX2020003421A (es) 2017-10-10 2020-07-20 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
MA52137A (fr) 2018-03-23 2021-01-27 Eidos Therapeutics Inc Méthodes de traitement de l'amylose ttr à l'aide d'ag10
AU2019259798A1 (en) 2018-04-24 2020-11-12 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
EP3806856A1 (en) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
CN108836091B (zh) * 2018-06-27 2020-12-04 贵州筑信达创科技有限公司 导轨
CN108533609B (zh) * 2018-06-27 2020-03-10 贵州筑信达创科技有限公司 导轨及滑动件的组合结构
EP3814327A1 (en) 2018-06-29 2021-05-05 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
AU2019321583C1 (en) 2018-08-17 2025-11-27 Eidos Therapeutics, Inc. Formulations of AG10
AU2019352017A1 (en) 2018-10-03 2021-05-06 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
AU2019363368A1 (en) 2018-10-16 2021-05-13 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
WO2020118042A1 (en) 2018-12-05 2020-06-11 Jacobs Wagner Christine Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of lyme disease-related pathologies
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP7239216B2 (ja) 2018-12-27 2023-03-14 ニューラクル サイエンス カンパニー リミテッド 粥状硬化症を治療するための抗ｆａｍ１９ａ５抗体の使用
CN113195533B (zh) 2019-01-02 2024-04-26 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
ES2978570T3 (es) 2019-02-26 2024-09-16 Inspirna Inc Anticuerpos anti-MERTK de alta afinidad y sus usos
WO2020181165A1 (en) 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Caspase inhibitors and methods of use thereof
CN114222802B (zh) 2019-05-20 2025-07-11 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
JP7754724B2 (ja) 2019-05-20 2025-10-15 ニルバナ サイエンシーズ インク． 発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
AU2020311404A1 (en) 2019-07-11 2022-03-03 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
AU2020310190A1 (en) 2019-07-11 2022-02-24 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20220053007A (ko) 2019-08-30 2022-04-28 아게누스 인코포레이티드 항-cd96 항체 및 이의 사용 방법
JP7566889B2 (ja) 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド Ｉｌ－１７ａモジュレーターおよびその使用
KR102337657B1 (ko) * 2019-11-06 2021-12-09 한국철도기술연구원 철도진동저감용 조립식 블록 및 이를 이용한 블록 구조물
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
CN113136745B (zh) * 2020-01-17 2024-10-25 洛阳双瑞橡塑科技有限公司 一种轨道道床吸音减振装置
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US12006643B2 (en) * 2020-05-27 2024-06-11 Mute Wall Systems, Inc. Sound dampening barrier wall
EP4157271A1 (en) 2020-05-29 2023-04-05 Boulder Bioscience LLC Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP4149471A4 (en) 2020-06-30 2024-07-10 Prosetta Biosciences, Inc. ISOQUINOLINE DERIVATIVES, PROCESSES FOR THE SYNTHESIS AND USES THEREOF
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
CN116615236A (zh) 2020-11-05 2023-08-18 新免疫技术有限公司 用il-7蛋白和核苷酸疫苗的组合治疗肿瘤的方法
CN112712784B (zh) * 2020-11-30 2024-12-31 南京华秦光声科技有限责任公司 一种低频宽带平板吸声结构
AU2021402911A1 (en) 2020-12-14 2023-07-06 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
JP2024520676A (ja) 2021-06-02 2024-05-24 ライエル・イミュノファーマ・インコーポレイテッド Ｎｒ４ａ３欠損免疫細胞及びその使用
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
JP2024522768A (ja) 2021-06-16 2024-06-21 バイオセリックス， インコーポレイテッド Ｓｏｓ１タンパク質分解剤、その医薬組成物及びそれらの治療的応用
US20240277857A1 (en) 2021-09-29 2024-08-22 Nbios, Inc. Coiled-coil fusion protein
AU2022368836A1 (en) 2021-10-22 2024-05-02 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
EP4456907A1 (en) 2021-12-30 2024-11-06 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
JP2025501308A (ja) 2022-01-03 2025-01-17 ライラック セラピューティクス， インク． 非環式チオールプロドラッグ
WO2023157989A1 (ko) 2022-02-17 2023-08-24 주식회사 노벨티노빌리티 항체-약물 접합체
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー， インク． ニコチン酸及びリボースから誘導体化した新規プロドラッグ
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
AR129053A1 (es) 2022-04-14 2024-07-10 Bristol Myers Squibb Co Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos
AU2023265665A1 (en) 2022-05-05 2024-10-10 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
IL316794A (en) 2022-05-10 2025-01-01 Biotheryx Inc CDK protease inhibitors, pharmaceuticals and therapeutic applications
KR20250027283A (ko) 2022-05-19 2025-02-25 라이엘 이뮤노파마, 인크. nr4a3을 표적하는 폴리뉴클레오타이드 및 이의 용도
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
EP4593826A1 (en) 2022-09-30 2025-08-06 Boulder Bioscience LLC Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
JP2025537484A (ja) 2022-10-21 2025-11-18 ダイアゴナル・セラピューティクス・インコーポレイテッド Ｉｌ－１８受容体に対するヘテロマーアゴニスト抗体
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
EP4608838A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
KR20250089492A (ko) 2022-11-07 2025-06-18 네오이뮨텍, 인코퍼레이티드 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
EP4626864A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
KR102870410B1 (ko) * 2022-12-09 2025-10-16 한국전자기술연구원 방음재 및 소음 제어 시스템
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
EP4688147A1 (en) 2023-04-07 2026-02-11 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
AU2024254039A1 (en) 2023-04-07 2025-10-02 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
TW202448485A (zh) 2023-05-05 2024-12-16 美商拜奧馬林製藥公司 肌萎縮蛋白外顯子跳躍寡核苷酸
EP4709725A1 (en) 2023-05-09 2026-03-18 Progentos Therapeutics, Inc. Heterocyclic compounds and uses thereof
AU2024276812A1 (en) 2023-05-19 2025-11-06 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
KR20260033048A (ko) 2023-07-03 2026-03-10 네오이뮨텍, 인코퍼레이티드 이종이합체 fc 분자 및 이의 용도
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
AU2024344247A1 (en) 2023-09-19 2026-05-07 Kancure Pte. Ltd. Survivin-targeted compounds
IL327069A (en) 2023-09-27 2026-05-01 Isosterix Inc Mist inhibitors
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
AU2024366926A1 (en) 2023-10-23 2026-03-12 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators
WO2026080748A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Bone morphogenetic protein receptor type 2 (bmprii) antibodies
WO2026080752A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. De novo antibodies to activin a receptor like type 1 (alk1)
WO2026080757A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Activin receptor type ii a/b (actriia/b) antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991848A (en) * 1974-08-16 1976-11-16 Frigitemp Acoustical board
US4142468A (en) * 1976-04-20 1979-03-06 Charles Birnstiel Elevated rail transit guideway with noise attenuators
US4093120A (en) 1977-01-24 1978-06-06 Park Rubber Company Railroad crossing structure
DE7711191U1 (de) 1977-04-07 1978-09-28 Straetner Geb. Buss, Anita, 4300 Essen Fahrbahnplatte fuer schienengleiche bahnuebergaenge
DE7719283U1 (de) 1977-06-20 1977-10-27 Gummiwerk Kraiburg Gmbh & Co, 8264 Waldkraiburg Platte fuer schienengleiche bahnuebergaenge
DE3602313A1 (de) * 1986-01-27 1987-07-30 Clouth Gummiwerke Ag Schallabsorbierender laermschutz insbesondere fuer schotterlose gleise
DE3827547C2 (de) * 1988-08-13 2000-09-21 Zueblin Ag Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
US4960184A (en) * 1989-11-09 1990-10-02 Bruce Woodward Sound absorbing structure
DE4243102A1 (en) * 1991-12-20 1993-07-01 Bold Karl Gmbh & Co Noise protection and sight wall with carrier girder construction
DE69405881T2 (de) * 1994-02-11 1998-03-19 Autostrade Concess Const Schalldämpfender strassenbelag und verfahren zu dessen herstellung
DE4414566C2 (de) * 1994-04-27 1997-11-20 Freudenberg Carl Fa Luftschalldämpfer
DE4417402A1 (de) 1994-05-18 1995-11-23 Gruenzweig & Hartmann Montage Schallschutzeinrichtung zur Schalldämpfung und -dämmung an Gleiskörpern
NL194553C (nl) * 1994-06-06 2002-07-02 Veldhoen Raalte B V Inrichting voor de geluidsisolatie van een spoorbaan.
DE29515935U1 (de) * 1995-10-07 1995-11-30 Deutsche Asphalt GmbH, 63263 Neu-Isenburg Schallabsorber für einen schotterlosen Eisenbahnoberbau
IT1293307B1 (it) * 1997-07-09 1999-02-16 Dieselbox Sa Barriera antirumore a pannelli trasparenti,dotata di caratteristiche fonoisolanti e fonoassorbenti

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530413A (ja) * 2013-07-07 2016-09-29 ４・サイレンス・ベスローテン・フエンノートシャップ４Ｓｉｌｅｎｃｅ Ｂ．Ｖ． 音を回折させるための回折器

Also Published As

Publication number Publication date
EP0901536A1 (de) 1999-03-17
NO316078B1 (no) 2003-12-08
ES2186891T3 (es) 2003-05-16
WO1997045592A1 (de) 1997-12-04
CA2255946A1 (en) 1997-12-04
AU738889B2 (en) 2001-09-27
US6253872B1 (en) 2001-07-03
HUP9903612A2 (hu) 2000-02-28
HUP9903612A3 (en) 2001-08-28
NO985600L (no) 1998-11-30
CA2255946C (en) 2006-03-14
CN100424268C (zh) 2008-10-08
HU221872B1 (hu) 2003-02-28
TW345603B (en) 1998-11-21
DK0901536T3 (da) 2003-04-07
CN1219989A (zh) 1999-06-16
AU2880197A (en) 1998-01-05
DE59708955D1 (de) 2003-01-23
JP2000510921A (ja) 2000-08-22
EP0901536B1 (de) 2002-12-11
NO985600D0 (no) 1998-11-30
ATE229595T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
JP2000510921A (ja) 軌道用の防音装置
IL189167A (en) Fixed track for rail vehicles
KR101817142B1 (ko) 소음 저감을 위한 하로교 u형 거더 및 그 시공 방법
KR100377679B1 (ko) 흡음형 방음판넬
CN103452015A (zh) 轨道吸音板结构
EP0626023A1 (en) Noise suppression systems
NL2016280B1 (nl) Bestratingselement.
JP3505588B2 (ja) 軌道用吸音構造
RU2176004C2 (ru) Защитный экран для придорожного шумопоглощения
CN108630188B (zh) 吸声结构、吸声组件、组装系统及吸声结构的加工工艺
JP2007262669A (ja) 吸音板構造及び該吸音板構造を用いた道路用遮音壁
JP3914395B2 (ja) 騒音低減装置とそれを取り付けた遮音壁及びその取付方法
CN219430405U (zh) 一种适用于站城一体化综合开发的高等级减振轨道结构
KR102871285B1 (ko) 트랙 구성요소
CN208995841U (zh) 有砟轨道道床
JP3914382B2 (ja) 遮音壁
JP2975407B2 (ja) ゴムパット付き枕木の製法
JP2968494B2 (ja) 高架橋の恒久足場
JP4091836B2 (ja) 鉄道用防音壁
JP3450309B2 (ja) 軌道カバリング
JP2821900B2 (ja) 音波制御装置を配置した輸送用高架構造物
JP2753826B2 (ja) 高架橋用吸音部材
JP2004042735A (ja) 車両用スカート体
JP6944840B2 (ja) 防音壁
KR100984160B1 (ko) 철도용 소음방지시스템

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040521

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20040701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060623

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090630

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100630

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110630

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110630

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120630

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130630

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees